Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot help end HIV? new study tests digital tool in black MSM

NCT ID NCT05968755

Prevention Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study will test a chatbot designed to increase awareness and use of PrEP, a daily pill that prevents HIV, among Black men who have sex with men (MSM) in the Southern United States. About 145 participants will interact with the chatbot over 90 days, answering questions and receiving personalized PrEP information. The goal is to see if the chatbot can help more men learn about and start taking PrEP, potentially reducing HIV rates in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chatbot
What this could lead to
If successful, this chatbot could become a low-cost tool to increase PrEP use and reduce HIV rates in a high-risk community.
What could go wrong
This is a small, early-stage trial with no control group, so results may not be generalizable. The chatbot's impact on actual HIV prevention is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 145 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being cisgender Black male * Being aged ≥ 18 years * Having Internet access * Speaking English * Self-reporting condomless sex with another man in the past 6 months * HIV negative or untested. Exclusion Criteria: * Having lived in the US South less than 3 months * Having received antiretroviral therapy (ART) treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV prevention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV prevention Prep awareness Prep uptake

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Care 4 U Community Health Center

    Miami, Florida, 33127, United States

  • Community Care Resources of FL (CCRSFL)

    Pembroke Pines, Florida, 33027, United States

  • NAESM, Inc

    Atlanta, Georgia, 30318, United States

  • RAO Community Health

    Charlotte, North Carolina, 28202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.